Takeda Pharmaceuticals to Acquire Nycomed

The transaction is expected to transform Takeda's global business, in line with Takeda's sustainable growth strategy as it was outlined in its 2011-2013 mid-range plan. Takeda has a strong presence in the Japanese and US markets, while Nycomed has a significant business infrastructure in Europe and high-growth emerging markets that will enhance Takeda's regulatory development expertise and commercialization capability. The acquisition includes the roflumilast franchise, a first-in-class treatment for chronic obstructive pulmonary disease (COPD), which is expected to be a major source of revenue growth for Takeda. In addition, the acquisition will bring Takeda an immediate and stable increase in cash flow with Nycomed's more than EUR 2.8 billion in annual revenue, excluding the US Dermatology business, which is not included in the purchase. The transaction is expected to be completed within 90-120 days.

"Nycomed enables Takeda to maximize the value of our portfolio and gives us an immediate strong presence in the high-growth emerging markets while doubling Takeda's European sales," said Yasuchika Hasegawa, president and CEO of Takeda. "Nycomed's strength in a geographically wide range of markets and its diverse talent base will be a strong driver to helping us realize our important mission of striving toward better health for patients worldwide through leading innovation in medicine."

"The combination of Takeda's successful track record of innovation with Nycomed's efficient commercialization and manufacturing infrastructure will create a global player with a phenomenal ability to bring medicines to patients and healthcare providers around the world," said Håkan Björklund, CEO of Nycomed.

Nycomed is a privately owned pharmaceutical company with a diversified product portfolio that includes both established prescription pharmaceutical products as a primary revenue driver, and over the counter (OTC) products. It has a strong European commercial network and it is aggressively growing in emerging markets, which account for more than 50% of global pharmaceutical growth.

Related Links:
Takeda Pharmaceutical Company
Nycomed